menu search

IOBT / IO Biotech Announces Participation in Upcoming Investor Conferences

IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced its participation in the upcoming investor conferences: Read More
Posted: Sep 6 2023, 08:35
Author Name: GlobeNewsWire
Views: 042117

IOBT News  

IO Biotech Announces Participation in Upcoming Investor Conferences

By GlobeNewsWire
September 6, 2023

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating more_horizontal

IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study

By Zacks Investment Research
June 15, 2023

IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study

IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO1 more_horizontal

IO Biotech to Present at the Jefferies Healthcare Conference

By GlobeNewsWire
May 30, 2023

IO Biotech to Present at the Jefferies Healthcare Conference

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating c more_horizontal


Search within

Pages Search Results: